Hypogonadism and chronic obstructive pulmonary disease


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Chronic obstructive pulmonary disease (COPD) is a systemic disease that affects not only the respiratory system. Sex hormones deficiency in men can be correlated with the COPD stages and make a negative contribution during its progression. Up to date, there are no long-term trials evaluating the effects of androgens on the parameters of respiratory function in patients with COPD. Changes of testosterone levels in patients with COPD correlate with forced expiratory volume, and hypoxemia and hypercapnia levels. Glucocorticosteroids exacerbate androgen deficiency in patients with COPD, and the use of hormone replacement therapy with testosterone in these patients is justified. Androgens, in particular drug nebido, testosterone depot, can be effectively used in treatment and rehabilitation of patients with COPD.

Texto integral

Acesso é fechado

Bibliografia

  1. Mulligan T., Frick M.F., Zuraw Q.C. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J Clin. Pract. 2006;60(7):762—769.
  2. Creutzberg E.C., Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur. Respir. J Suppl. 2003;46:76s-80s.
  3. Makarevich A.E. Disorders of sex hormone status in patients with chronic obstructive pulmonary disease. WiadLek. 2003;56(3-4):140—146.
  4. Balasubramanian V., Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr. Opin. Pulm. Med. 2012;18(2):112—117.
  5. Подзолков В.И., Медведев И.Д., Ишина Т.И. и др. Сравнительная характеристика гормонального профиля у курящих и некурящих мужчин со стабильным течением хронической обструктивной болезни легких. Клиническая медицина. 2012;6:26-30.
  6. Velema M.S., Kwa B.H., de Ronde W. Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients? Curr. Opin. Pulm. Med. 2012;18(2):118-124.
  7. Canguven O/, Albayrak S. Do low testosterone levels contribute to the pathogenesis of asthma? Med. Hypotheses. 2011;76(4):585-588.
  8. Akbaş T., Karakurt S., Unlügüzel G. et al. The endocrinologic changes in critically ill chronic obstructive pulmonary disease patients. COPD. 2010;7(4):240-247.
  9. Svartberg J., Schirmer H., Medb0 A. et al. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Troms0 study. Eur. J Epidemiol. 2007; 22(2):107-112.
  10. Casaburi R. Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Baillieres. Clin. Endocrinol. Metab. 1998;12(3):407-418.
  11. Samaras N., Samaras D., Lang P.O. et al. Chronic obstructive pulmonary disease: risk and benefit of testosterone therapy.Rev. Med. Suisse. 2012;8(363):2224—2227.
  12. Halabi S., Collins E.G., Thorevska N. et al. Relationship between depressive symptoms and hypogonadism in men with COPD. COPD. 2011;8(5):346—353.
  13. Svartberg J. Androgens and chronic obstructive pulmonary disease. Curr. Opin. Endocrinol. Diabetes Obes. 2010;17(3):257-261.
  14. Karadag F., Ozcan H., Karul A.B. et al. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int. J Clin. Pract. 2009;63(2):275-281.
  15. Karadag F., Ozcan H., Karul A.B. et al. Correlates of erectile dysfunction in moderate-to-severe chronic obstructive pulmonary disease patients. Respirology. 2007;12(2):248-253.
  16. Collins E.G., Halabi S., Langston M. et al. Sexual dysfunction in men with COPD: impact on quality of life and survival. Lung. 2012;190(5):545—556.
  17. Svartberg J., Aasebø U., Hjalmarsen A. et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir. Med. 2004;98(9):906-913.
  18. Koehler F., Doehner W., Hoernig S. et al. Anorexia in chronic obstructive pulmonary disease - association to cachexia and hormonal derangement. Int. J Cardiol. 2007;119(1):83-89.
  19. Van Vliet M., Spruit M.A., Verleden G. et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am. J Respir. Crit. Care Med. 2005; 172(9):1105-1111.
  20. Casaburi R., Bhasin S., Cosentino L. et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am. J Respir. Crit. Care Med. 2004;170(8):870-878.
  21. Kamischke A., Kemper D.E., Castel M.A. et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur. Respir. J. 1998;11(1):41-45.
  22. Wan Z.H., Wen Y.B., Ding Q.F. et al. Effects of testosterone substitution on metabolic syndrome-related factors in hypogonadal males: a meta-analysis. Zhonghua Nan KeXue. 2010; 16(6):510-515.
  23. Bhasin S. et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin. Endocrinol. Metab. 2005;90(2):678-688.
  24. Burris A.S., Banks S.M., Carter C.S. et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13(4):297-304.
  25. Моргунов Л.Ю., Денисова И.А., Рожкова Т.И. и др. Андрогенный дефицит и его коррекция у мужчин, перенесших ишемический инсульт, с сахарным диабетом 2-го типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(8) :21—24.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013